Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Link
https://link.springer.com/content/pdf/10.1007/s10741-021-10211-9.pdf
Reference38 articles.
1. DeFronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13(1):11–26. https://doi.org/10.1038/nrneph.2016.170
2. Gronda E, Iacoviello M, Caldarola P, Benvenuto M, Cassaniti L, Palazzuoli A, Municinò A, Napoli C, Gabrielli D (2021) Inibitori del co-trasportatore sodio-glucosio di tipo 2: meccanismi d’azione renale. Le implicazioni nel diabete e nello scompenso cardiaco [Sodium-glucose co-transporter 2 inhibitors: mechanisms of renal action. Implications for diabetes and heart failure]. G Ital Cardiol (Rome) 22(4):284–291. Italian. https://doi.org/10.1714/3574.35574. PMID: 33783448
3. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752–772. https://doi.org/10.1161/CIRCULATIONAHA.116.021887 (Epub 2016 Jul 28 PMID: 27470878)
4. Liu JJ, Lee T, DeFronzo RA (2012) Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes 61(9):2199–2204. https://doi.org/10.2337/db12-0052.PMID:22923645;PMCID:PMC3425428
5. Matsubara M (2004) Renal sodium handling for body fluid maintenance and blood pressure regulation. Yakugaku Zasshi 124(6):301–309. https://doi.org/10.1248/yakushi.124.301 (PMID: 15170065)
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review;Metabolites;2024-05-06
2. Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease;Drug Discovery Today;2023-11
3. NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR DIABETES MELLITUS, HEART FAILURE AND KIDNEY DISEASE;FARMACIA;2023-08-31
4. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats;Biomedicine & Pharmacotherapy;2023-05
5. Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest;Journal of Clinical Medicine;2023-01-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3